Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Vitro Diagnostics: Innovation and Integration

Executive Summary

Integration is occuring at almost every level of the in vitro diagnostic industry--at the preclinical level to decrease drug development costs and timelines and at the clinical level to better manage diseases. In the lab, there's a demand for new tools to improve speed and efficiency, and new information systems to better integrate disparate data. At the same time, there has been a flurry of integration and consolidation at the market level, with 35 mergers and acquisitions in the last 12 months.

You may also be interested in...



Integrated Diagnostics and Personalized Care: An Interview With GE Healthcare

To capitalize on the rapidly growing personalized medicine space, large imaging companies have been diversifying and acquiring in companies with molecular diagnostic product lines and pipelines. Medtech Insight recently spoke with two executives from GE Healthcare: Joe Camaratta, general manager, GE Healthcare's Category Solutions and Marketing Group; and Robert Dann, oncology strategic marketing leader, GE Healthcare's Medical Diagnostics Division, who provided some details on the company's overall strategy for personalized medicine and what these developments might mean for the future of patient care.

Integrated Diagnostics and Personalized Care: An Interview With GE Healthcare

To capitalize on the rapidly growing personalized medicine space, large imaging companies have been diversifying and acquiring in companies with molecular diagnostic product lines and pipelines. Medtech Insight recently spoke with two executives from GE Healthcare: Joe Camaratta, general manager, GE Healthcare's Category Solutions and Marketing Group; and Robert Dann, oncology strategic marketing leader, GE Healthcare's Medical Diagnostics Division, who provided some details on the company's overall strategy for personalized medicine and what these developments might mean for the future of patient care.

In Vitro Diagnostics: The Quest For Growth

This article first appeared in Medtech Insight, October 2010.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel